5375-00-8

Usage

Uses

Used in Organic Synthesis:
1-Benzyloxy-3-iodopropane is used as a reagent in organic synthesis for its ability to facilitate the formation of new chemical bonds and reactions. Its presence in reactions can lead to the creation of a wide range of organic compounds, making it an essential component in the synthesis process.
Used in Pharmaceutical Synthesis:
1-Benzyloxy-3-iodopropane is used as a precursor in the synthesis of various pharmaceuticals. Its unique structure allows it to be a key building block in the development of new drugs, contributing to the advancement of medicine and healthcare.
Used in Agrochemical Synthesis:
In the agrochemical industry, 1-Benzyloxy-3-iodopropane is utilized as a precursor for the synthesis of various agrochemicals. Its application in this field helps in the development of new and effective products for agricultural use, such as pesticides and herbicides.
Used in Asymmetrical Carbon Compound Preparation:
1-Benzyloxy-3-iodopropane is used as a starting material for the preparation of asymmetrical carbon compounds in organic chemistry. Its role in this process is crucial for the synthesis of complex organic molecules with unique properties and potential applications in various fields.
Used in Drug Development:
1-Benzyloxy-3-iodopropane has been studied for its potential use in the development of new drugs and drug delivery systems. Its unique properties and reactivity make it a promising candidate for the creation of innovative pharmaceuticals and improving drug delivery mechanisms, ultimately contributing to better treatment options and patient outcomes.

Upstream product

• 26420-79-1 1-chloro-3-benzyloxypropane 
• 98518-10-6 3-benzyloxy-1-propanol methanesulfonate 
• 120758-24-9 1-benzyloxy-3-tosyloxypropane 
• 4799-68-2 3-benzyloxypropan-1-ol 
• 100-39-0 benzyl bromide 
• 504-63-2 trimethyleneglycol 
• 14593-43-2 benzyl allyl ether 
• 100-44-7 benzyl chloride 

Downstream Products

• 51270-22-5 methyl 7-benzyloxy-3-oxo-heptanoate 
• 141062-33-1 (S)-6-Benzyloxy-2-[(E)-(S)-2-methoxymethyl-pyrrolidin-1-ylimino]-3-methyl-hexanoic acid 2,6-di-tert-butyl-4-methoxy-phenyl ester 
• 141087-96-9 (R)-6-Benzyloxy-2-[(E)-(R)-2-methoxymethyl-pyrrolidin-1-ylimino]-3-methyl-hexanoic acid 2,6-di-tert-butyl-4-methoxy-phenyl ester 
• 81593-63-7 1-(3-benzoyloxypropyl)-7-methoxyisoquinoline 
• 130482-73-4 5-(3-Benzyloxy-propyl)-4-oxo-pyrrolidine-1,3-dicarboxylic acid diethyl ester 
• 89118-14-9 methyl 2-acetyl-5-benzyloxypentanoate 
• 161693-54-5 (2R,5R,8aS)-2,5-Bis-(3-benzyloxy-propyl)-4-trifluoromethanesulfonyloxy-3,5,6,7,8,8a-hexahydro-2H-quinoline-1-carboxylic acid phenyl ester 
• 82258-55-7 Ethyl 5-benzyloxy-2-(ethoxycarbonyl)pentanoate 
• 501037-05-4 5-benzyloxy-1,1,1-trifluoro-pentan-2-one O-benzyl-oxime 
• 565194-14-1 (2R,3S,4Z)-7-benzyloxy-1,2-bis(tert-butyldimethylsilyloxy)-3-methylhept-4-ene 
• 607405-54-9 (1S,2S,4S,5R)-2-[3-(benzyloxy)propyl]-4,7,7-trimethyl-5-[(tetrahydro-2H-pyran-2-yl)oxy]bicyclo[2.2.1]heptan-2-ol 
• 796866-62-1 (2'S,6R)-6-[(3'-benzyloxy)propyl]-1-methoxy-6-[[2'-(methoxymethyl)pyrrolidinyl]carbonyl]-1,4-cyclohexadiene 
• 862370-51-2 N-[3-(benzyloxy)propyl]-N-[2-[[(tert-butylamino)carbonyl]amino]-3-phenyl-1,6-naphthyridin-7-yl]acetamide 
• 862370-12-5 1-[7-(3-benzyloxy-propylamino)-3-(3,5-dimethoxy-phenyl)-[1,6]naphthyridin-2-yl]-3-tert-butyl-urea 

Relevant academic research and scientific papers

Total Synthesis of the Diterpene Waihoensene

A racemic and scalable enantioselective total synthesis of (+)-waihoensene was accomplished. (+)-Waihoensene belongs to the diterpene natural product family, and it features an angular triquinane substructure motif. Its tetracyclic [6.5.5.5]backbone is al

Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds

A challenge in the development of novel 18F-labelled positron emission tomography (PET) imaging probes is identification of metabolically stable sites to incorporate the 18F radioisotope. Metabolic loss of 18F from PET probes in vivo can lead to misleading biodistribution data as displaced 18F can accumulate in various tissues. In this study we report on in vitro hepatic microsomal metabolism of novel caffeine containing bifunctional compounds (C8-6-I, C8-6-N, C8-6-C8) that can prevent in vitro aggregation of α-synuclein, which is associated with the pathophysiology of Parkinson’s disease. The metabolic profile obtained guided us to synthesize stable isotope 19F-labelled analogues in which the fluorine was introduced at the metabolically stable N7 of the caffeine moiety. An in vitro hepatic microsomal metabolism study of the 19F-labelled analogues resulted in similar metabolites to the unlabelled compounds and demonstrated that the fluorine was metabolically stable, suggesting that these analogues are appropriate PET imaging probes. This straightforward in vitro strategy is valuable for avoiding costly stability failures when designing radiolabelled compounds for PET imaging.

Selective alkyl ether cleavage by cationic bis(phosphine)iridium complexes

Catalysts capable of heterolytic silane activation have been successfully applied to the conversion of alkyl ethers to silyl ethers via C-O bond cleavage. The previously-reported cationic pincer-supported iridium complex for this transformation suffers fr

2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS

The invention provides a compound which is a diazine of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt thereof, for use as an antifungal agent: (I) wherein X, N', C', A and E are as defined herein. The invention also provides a compound of Formula (I) as defined herein.

AMINO PYRAZOLONE DERIVATIVE HAVING CONDENSED RING STRUCTURE

PROBLEM TO BE SOLVED: To provide a compound that has excellent inhibitory action on ATPase activity of TIP48/TIP49 complex and is therefore useful for the treatment of tumor, or a pharmacologically acceptable salt thereof. SOLUTION: The present invention provides a compound having a structure represented by general formula (I), its pharmacologically acceptable salt, or a pharmaceutical composition comprising the compound (where R3, R4, R5, R6, R7, W, X, Y, and Z are as defined in the specifications). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Discovery of a 5 H-benzo[4,5]cyclohepta[1,2-b ]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer

c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a number of approaches to disrupt aberrant c-Met signaling. Screening efforts identified a unique class of 5H-benzo[4,5] cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1. Subsequent SAR studies led to the development of 81 (MK-2461), a potent inhibitor of c-Met that was efficacious in preclinical animal models of tumor suppression. In addition, biochemical studies and X-ray analysis have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase. This report details the development of 81 and provides a description of its unique biochemical properties.

Asymmetric synthesis of (R)- and (S)-4-methyloctanoic acids. A new route to chiral fatty acids with remote stereocenters

The enantioselective synthesis of both enantiomers of 4-methyloctanoic acid, one major aggregation pheromone component of the rhinoceros beetles of the genus Oryctes and an important aroma compound, is described. The key step of the synthesis is based on

An efficient radical procedure for the halogenation and chalcogenation of B-alkylcatecholboranes

An efficient formal anti-Markovnikov addition of HX (X = Cl, Br, I, SR and SeR) to olefins under mild reaction conditionsisdes cribed. The procedure isbas ed on the hydroboration of alkeneswith catecholborane. The conversion of the intermediate B-alkylcatecholboranesto the corresponding halides, sulfides and selenides is based on a common process, i.e., generation of a radical from the alkylborane followed by abstraction of a heteroatom from an aromatic sulfonyl reagent. The efficiency of these radical reactionsis remarkable. The mildness of the reaction conditions is well illustrated by the preparation of iodoalkanes. Despite the notorious reactivity of iodoalkanes under radical reaction conditions, no product degradation wasobs erved.

Silver ion-induced grob fragmentation of γ-amino iodides: Highly stereoselective synthesis of polysubstituted piperidines

(Chemical Equation Presented) A new concerted silver ion-mediated Grob fragmentation process is described in which a 1,2-dihydropyridinium ion is formed and trapped in situ with Grignard reagents in a highly regio- and diastereoselective fashion. Using th

Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases

7-Substituted 3-aryl-1,6-naphthyridine-2,7-diamines and related 2-ureas are inhibitors of fibroblast growth factor receptor-1 (FGFR-1) and vascular endothelial growth factor receptor-2 (VEGFR-2). 3-(3,5-Dimethoxyphenyl) and 3-phenyl analogues were prepared from 7-acetamido-2-teri-butylureas by alkylation with benzyl ω-iodoalkyl ethers, debenzylation, and animation, followed by selective cleavage of the 7-N-acetamide. 3-(2,6-Dichlorophenyl) analogues were prepared from the 7-fluoro-2-amine by displacement with substituted alkylamines, followed by selective acylation of the resulting substituted naphthyridine-2,7-diamines with alkyl isocyanates. The 3-(3,5-dimethoxyphenyl) derivatives were low nanomolar inhibitors of both FGFR and VEGFR and were highly selective (>100-fold) over PDGFR and c-Src. Variations in the base strength or spatial position of the 7-side chain base had only small effects on the potency (5-fold) or selectivity (20-fold). The 3-(2,6-dichlorophenyl)-2-urea derivatives were slightly less active against VEGFR and less selective, being more effective against PDGFR (ca. 10-fold) and c-Src (ca. 500-fold). The 3-(3,5-dimethoxyphenyl)-1,6-naphthyridines were generally more potent than the corresponding pyrido[2,3-d]pyrimidines against both VEGFR and FGFR (2- to 20-fold), with only slightly increased PDGFR and c-Src activity. The 3-(3,5-dimethoxyphenyl)-1,6-naphthyridine 2-ureas were also low nanomolar inhibitors of the growth of human umbilical vein endothelial cells (HUVECs) stimulated by serum, FGF, or VEGF, at concentrations that did not affect the growth of representative tumor cell lines, and were more (3- to 65-fold) potent than the corresponding pyrido[2,3-d]pyrimidines.